Total Payments
$37,121
2024 Payments
$23.14
Companies
19
Transactions
48
Medicare Patients
324
Medicare Billing
$28,673
Payment Breakdown by Category
Consulting$17,520 (47.2%)
Research$15,585 (42.0%)
Other$2,412 (6.5%)
Food & Beverage$777.01 (2.1%)
Travel$636.27 (1.7%)
Education$189.95 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,520 | 12 | 47.2% |
| Unspecified | $15,585 | 10 | 42.0% |
| Honoraria | $1,512 | 1 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $900.00 | 4 | 2.4% |
| Food and Beverage | $777.01 | 11 | 2.1% |
| Travel and Lodging | $636.27 | 8 | 1.7% |
| Education | $189.95 | 2 | 0.5% |
Payments by Type
General
$21,536
38 transactions
Research
$15,585
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Becton, Dickinson and Company | $15,525 | 8 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $5,150 | 2 | $0 (2020) |
| Incyte Corporation | $4,420 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $4,065 | 10 | $0 (2022) |
| Puma Biotechnology, Inc. | $2,371 | 6 | $0 (2019) |
| MorphoSys, US Inc. | $1,687 | 5 | $0 (2022) |
| Blueprint Medicines Corporation | $1,512 | 1 | $0 (2021) |
| Astellas Pharma US Inc | $599.95 | 2 | $0 (2022) |
| SWEDISH ORPHAN BIOVITRUM AB | $425.49 | 1 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $350.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23.14 | 1 | Genmab U.S., Inc. ($23.14) |
| 2023 | $210.00 | 1 | Amneal Pharmaceuticals LLC ($210.00) |
| 2022 | $11,588 | 19 | Incyte Corporation ($4,420) |
| 2021 | $5,562 | 6 | Becton, Dickinson and Company ($3,300) |
| 2020 | $3,825 | 3 | AstraZeneca Pharmaceuticals LP ($2,800) |
| 2019 | $1,351 | 4 | Puma Biotechnology, Inc. ($1,201) |
| 2018 | $11,530 | 9 | Becton, Dickinson and Company ($10,200) |
| 2017 | $3,032 | 5 | AstraZeneca Pharmaceuticals LP ($2,350) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Oncology | ||||||
| 04/15/2023 | Amneal Pharmaceuticals LLC | — | Consulting Fee | In-kind items and services | $210.00 | General |
| 12/09/2022 | MorphoSys, US Inc. | — | Consulting Fee | Cash or cash equivalent | $1,455.00 | General |
| 12/09/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 12/09/2022 | MorphoSys, US Inc. | — | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| 12/09/2022 | MorphoSys, US Inc. | — | Travel and Lodging | Cash or cash equivalent | $25.30 | General |
| 12/09/2022 | MorphoSys, US Inc. | — | Travel and Lodging | Cash or cash equivalent | $20.30 | General |
| 11/10/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 11/10/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $100.23 | General |
| 11/10/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $47.99 | General |
| 11/10/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $9.80 | General |
| 11/10/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $7.25 | General |
| 10/26/2022 | MorphoSys, US Inc. | — | Food and Beverage | In-kind items and services | $154.64 | General |
| 10/26/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $114.52 | General |
| 10/26/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $53.46 | General |
| 10/26/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $14.00 | General |
| 10/25/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $358.07 | General |
| 03/19/2022 | Becton, Dickinson and Company | — | — | Cash or cash equivalent | $1,275.00 | Research |
| Study: YODA | ||||||
| 02/15/2022 | Incyte Corporation | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| Category: Oncology | ||||||
| 01/20/2022 | Incyte Corporation | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| Category: Oncology | ||||||
| 01/03/2022 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| 12/17/2021 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,512.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/07/2021 | Astellas Pharma US Inc | XOSPATA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $90.00 | General |
| Category: Oncology | ||||||
| 07/10/2021 | Becton, Dickinson and Company | — | — | Cash or cash equivalent | $150.00 | Research |
| Study: SUST080 • Category: Preanalytical Systems | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SUST 014 | Becton, Dickinson and Company | $5,550 | 1 |
| COS High Spiking | Becton, Dickinson and Company | $3,150 | 1 |
| PLATO06 | Becton, Dickinson and Company | $3,000 | 1 |
| SUST 015 | Becton, Dickinson and Company | $1,650 | 1 |
| YODA | Becton, Dickinson and Company | $1,275 | 1 |
| IDS-21SUST064 | Becton, Dickinson and Company | $600.00 | 1 |
| SUST 014 | BECTON, DICKINSON AND COMPANY | $150.00 | 1 |
| SUST080 | Becton, Dickinson and Company | $150.00 | 1 |
| A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Rifaximin From Two Formulations of Xifaxin 550 mg Tablets and the Dose Proportionality of Xifaxin 200, 400 and 600 mg in Health Subjects | Bausch Health US, LLC | $60.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 232 | 409 | $59,728 | $21,325 |
| 2022 | 2 | 50 | 71 | $12,732 | $4,633 |
| 2021 | 2 | 29 | 41 | $6,374 | $2,121 |
| 2020 | 1 | 13 | 16 | $2,240 | $593.63 |
Total Patients
324
Total Services
537
Medicare Billing
$28,673
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 57 | 142 | $18,816 | $6,894 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 101 | $18,848 | $6,848 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 81 | $10,730 | $3,763 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 23 | $4,268 | $1,252 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $2,912 | $1,230 | 42.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 26 | $2,159 | $682.75 | 31.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 20 | 24 | $1,995 | $655.44 | 32.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 28 | 48 | $8,454 | $2,886 | 34.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 22 | 23 | $4,278 | $1,747 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 28 | $5,152 | $1,744 | 33.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 12 | 13 | $1,222 | $377.19 | 30.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 13 | 16 | $2,240 | $593.63 | 26.5% |
About Dr. Igor Genkin, MD
Dr. Igor Genkin, MD is a Hematology & Oncology healthcare provider based in Salem, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700802972.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Igor Genkin, MD has received a total of $37,121 in payments from pharmaceutical and medical device companies, with $23.14 received in 2024. These payments were reported across 48 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($17,520).
As a Medicare-enrolled provider, Genkin has provided services to 324 Medicare beneficiaries, totaling 537 services with total Medicare billing of $28,673. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Salem, OH
- Active Since 07/14/2006
- Last Updated 01/04/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700802972
Products in Payments
- BD Vacutainer (Device) $7,200
- LYNPARZA (Drug) $5,150
- MONJUVI (Drug) $4,420
- Nerlynx (Drug) $2,371
- AYVAKIT (Drug) $1,512
- XOSPATA (Drug) $500.00
- JEVTANA (Drug) $350.00
- NIEMANN-PICK B (Drug) $250.00
- BD VACUTAINER (Device) $150.00
- UNITUXIN (Drug) $100.00
- IMBRUVICA (Drug) $90.00
- Avastin (Biological) $65.00
- RIFAXIMIN (Drug) $60.00
- Tivdak (Drug) $23.14
- ERBITUX (Drug) $16.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Salem
Dr. Paul Richards, M.d, M.D
Hematology & Oncology — Payments: $29,258
Hematology & Oncology $29,258
Dr. Vandana Karri, Md, MD
Hematology & Oncology — Payments: $15,833
Hematology & Oncology $15,833
Dr. Mark Currie, M.d, M.D
Hematology & Oncology — Payments: $15,478
Hematology & Oncology $15,478
Dr. William Pierce, M.d, M.D
Hematology & Oncology — Payments: $9,460
Hematology & Oncology $9,460
Janelle Meyer, Md, MD
Hematology & Oncology — Payments: $7,484
Hematology & Oncology $7,484
John Strother, M.d, M.D
Hematology & Oncology — Payments: $3,216
Hematology & Oncology $3,216